Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
15 June 2017
In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
22 May 2017
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as…
New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
7 March 2017
Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the…
Incentives for New Drugs to Tackle Anti-Microbial Resistance
1 May 2017
Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage…
‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
1 May 2017
The Oxford Biomedical Research Centre (BRC) was established in April 2007. OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of…
OHE at AES 2016: Early Access Schemes, Equity Adjusted QALYs, Multi-indication Pricing and Formulary Development
2 August 2016
The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the…
OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology
14 July 2016
On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned…